In one paragraphArticle in Circulation. Heart failure, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from itWhat it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
27 authors.
Mattia Zampieri *Department of Clinical and Experimental Medicine, Tuscan Regional Amyloidosis Centre, Careggi University Hospital, Florence, Italy (M. Zampieri, G.B., A.D.F., V.F., A.A., C.M., C.F., F.P., F.C.).ORCID 0000-0002-1140-134X Giulia Biagioni *Department of Clinical and Experimental Medicine, Tuscan Regional Amyloidosis Centre, Careggi University Hospital, Florence, Italy (M. Zampieri, G.B., A.D.F., V.F., A.A., C.M., C.F., F.P., F.C.).
Annamaria Del FrancoDepartment of Clinical and Experimental Medicine, Tuscan Regional Amyloidosis Centre, Careggi University Hospital, Florence, Italy (M. Zampieri, G.B., A.D.F., V.F., A.A., C.M., C.F., F.P., F.C.).ORCID 0000-0003-1405-9436 Marco CanepaCardiology Unit, Ospedale Policlinico San Martino IRCCS, Genoa, Italy (M.C., I.P., M.E.L.).ORCID 0000-0001-9063-5576 Italo PortoCardiology Unit, Ospedale Policlinico San Martino IRCCS, Genoa, Italy (M.C., I.P., M.E.L.).ORCID 0000-0002-9854-5046 Margherita ZanolettiDepartment of Internal Medicine, University of Genova, Italy (M.C., I.P., M. Zanoletti).ORCID 0009-0001-4379-4870 Marianna Eleonora LabateCardiology Unit, Ospedale Policlinico San Martino IRCCS, Genoa, Italy (M.C., I.P., M.E.L.).
Aldostefano PorcariCardiovascular Department, Centre for Diagnosis and Treatment of Cardiomyopathies, Azienda Sanitaria Universitaria Giuliano-Isontina (ASUGI), University of Trieste, Italy (A. Porcari, L.B., M.M., G. Sinagra).ORCID 0000-0003-3307-0825 Luca BordignonCardiovascular Department, Centre for Diagnosis and Treatment of Cardiomyopathies, Azienda Sanitaria Universitaria Giuliano-Isontina (ASUGI), University of Trieste, Italy (A. Porcari, L.B., M.M., G. Sinagra).
Marco MerloCardiovascular Department, Centre for Diagnosis and Treatment of Cardiomyopathies, Azienda Sanitaria Universitaria Giuliano-Isontina (ASUGI), University of Trieste, Italy (A. Porcari, L.B., M.M., G. Sinagra).ORCID 0000-0002-1022-3131 Gianfranco SinagraCardiovascular Department, Centre for Diagnosis and Treatment of Cardiomyopathies, Azienda Sanitaria Universitaria Giuliano-Isontina (ASUGI), University of Trieste, Italy (A. Porcari, L.B., M.M., G. Sinagra).ORCID 0000-0003-2700-8478 Giacomo TiniDipartimento di Medicina Clinica e Molecolare, Sapienza Università di Roma, Italy (G.T., B.M., E. Barbato).ORCID 0000-0001-8520-152X Beatrice MusumeciDipartimento di Medicina Clinica e Molecolare, Sapienza Università di Roma, Italy (G.T., B.M., E. Barbato).ORCID 0000-0003-4872-7981 Emanuele BarbatoDipartimento di Medicina Clinica e Molecolare, Sapienza Università di Roma, Italy (G.T., B.M., E. Barbato).ORCID 0000-0002-0050-5178 Elena BiaginiEuropean Reference Network for rare, low prevalence and complex diseases of the heart (ERN GUARD-Heart) (A. Porcari, L.B., M.M., G. Sinagra, E. Biagini, S.L.).ORCID 0000-0003-0295-0440 Simone LonghiEuropean Reference Network for rare, low prevalence and complex diseases of the heart (ERN GUARD-Heart) (A. Porcari, L.B., M.M., G. Sinagra, E. Biagini, S.L.).ORCID 0000-0002-7512-1179 Giuseppe SenaCardiology Unit, Cardiac Thoracic and Vascular Department, IRCCS Azienda Ospedaliero- Universitaria di Bologna, Italy (E. Biagini, S.L., G. Sena, A. Ponziani, G. Saturi).ORCID 0009-0009-6469-3786 Alberto PonzianiCardiology Unit, Cardiac Thoracic and Vascular Department, IRCCS Azienda Ospedaliero- Universitaria di Bologna, Italy (E. Biagini, S.L., G. Sena, A. Ponziani, G. Saturi).ORCID 0000-0001-5090-265X Giulia SaturiCardiology Unit, Cardiac Thoracic and Vascular Department, IRCCS Azienda Ospedaliero- Universitaria di Bologna, Italy (E. Biagini, S.L., G. Sena, A. Ponziani, G. Saturi).ORCID 0000-0002-8154-3538 Vera FicoDepartment of Clinical and Experimental Medicine, Tuscan Regional Amyloidosis Centre, Careggi University Hospital, Florence, Italy (M. Zampieri, G.B., A.D.F., V.F., A.A., C.M., C.F., F.P., F.C.).ORCID 0009-0006-6149-7278 Alessia ArgiròDepartment of Clinical and Experimental Medicine, Tuscan Regional Amyloidosis Centre, Careggi University Hospital, Florence, Italy (M. Zampieri, G.B., A.D.F., V.F., A.A., C.M., C.F., F.P., F.C.).ORCID 0000-0002-6394-9948 Carlotta MazzoniDepartment of Clinical and Experimental Medicine, Tuscan Regional Amyloidosis Centre, Careggi University Hospital, Florence, Italy (M. Zampieri, G.B., A.D.F., V.F., A.A., C.M., C.F., F.P., F.C.).ORCID 0000-0003-1330-7223 Carlo FumagalliDepartment of Clinical and Experimental Medicine, Tuscan Regional Amyloidosis Centre, Careggi University Hospital, Florence, Italy (M. Zampieri, G.B., A.D.F., V.F., A.A., C.M., C.F., F.P., F.C.).ORCID 0000-0001-7963-5049 Iacopo OlivottoCardiomyopathy Unit, Careggi University Hospital, Florence, Italy (M. Zampieri, G.B., A.D.F., V.F., A.A., C.M., C.F., I.O., F.C.).ORCID 0000-0003-1751-9266 Federico PerfettoDepartment of Clinical and Experimental Medicine, Tuscan Regional Amyloidosis Centre, Careggi University Hospital, Florence, Italy (M. Zampieri, G.B., A.D.F., V.F., A.A., C.M., C.F., F.P., F.C.).ORCID 0000-0003-0276-8331 Francesco CappelliDepartment of Clinical and Experimental Medicine, Tuscan Regional Amyloidosis Centre, Careggi University Hospital, Florence, Italy (M. Zampieri, G.B., A.D.F., V.F., A.A., C.M., C.F., F.P., F.C.).ORCID 0000-0002-1622-0732 Funding
No grant is acknowledged in the PubMed record.
6 · The paper itselfAbstract
backgroundThe tenet of cardiac amyloidosis (CA) as a paradigm of heart failure with restrictive ventricular physiology and preserved systolic function has come under scrutiny. We aimed to evaluate the prevalence and clinical significance of left ventricular (LV) systolic dysfunction versus restriction in a large real-world cohort with CA, assessed at the time of diagnosis.
methodsWe retrospectively analyzed 540 TTR (transthyretin)-CA and 280 AL (light chain)-CA. Patients were divided into 3 LV phenotypes: (1) preserved LV function: LV ejection fraction >40% associated with grade I diastolic dysfunction; (2) restriction: LV ejection fraction >40% associated with grade II/III diastolic dysfunction; (3) systolic dysfunction: LV ejection fraction ≤40% irrespective of diastolic function. We analyzed the progression from preserved LV function towards the other 2 LV phenotypes and survival free from the composite end point of all-cause mortality and heart transplantation.
resultsIn TTR-CA, the prevalence of preserved LV function was 32.0%, restriction was 56.1%, and systolic dysfunction was 11.9%. Among patients with preserved LV function, at the last evaluation, the conversion rate to restriction was 16.3% and to systolic dysfunction was 1.8%. The 3-year freedom from the composite end point was 75%, 61%, and 44%, respectively. In AL-CA, the prevalence of preserved LV function was 32.9%, restriction was 58.6%, and systolic dysfunction was 8.5%. Among patients with preserved LV function, at the last evaluation, the conversion rate to restriction was 12.9%, and to systolic dysfunction was none. The 3-year freedom from the composite end point was 46%, 32%, and 21%, respectively.
conclusionsRestriction was the most common presenting phenotype, while preserved LV function represented approximately one-third. The rate of progression from preserved LV function towards restriction was high, whereas it was limited towards systolic dysfunction. Although patients with preserved LV function presented the best event-free survival, considering all-cause mortality and heart transplantation, compared with restriction or systolic dysfunction, these phenotypes are not independent predictors of this composite end point.
Indexed as
Amyloid Neuropathies, FamilialCardiomyopathiesHeart FailureImmunoglobulin Light-chain AmyloidosisPrealbuminVentricular Dysfunction, LeftVentricular Function, LeftAgedFemaleHeart TransplantationHumansMaleMiddle AgedPhenotypePrevalencePrognosisPrealbuminTTR protein, humanamyloidosisglomerular filtration rateheart failurephenotypestroke volume
Identifiers
PMID41732853
PMCPMC12986034
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390